CytomX Therapeutics, Inc. (CTMX) is a publicly traded Healthcare sector company. As of May 21, 2026, CTMX trades at $3.74 with a market cap of $761.96M and a P/E ratio of 0.00. CTMX moved +2.06% today. Year to date, CTMX is -9.71%; over the trailing twelve months it is +80.58%. Its 52-week range spans $0.40 to $8.21. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces CTMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CTMX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CTMX recently traded at $3.74. Market cap is $761.96M. P/E ratio is 0.00. Revenue is $35.54M.
| Metric | Value |
|---|---|
| Price | $3.74 |
| Market Cap | $761.96M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.21 |
| 52-Week Low | $0.40 |
| Volume | 759 |
| Avg Volume | 0 |
| Revenue (TTM) | $35.54M |
| Net Income | $-59.14M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $76.20M | $-17.37M | $0.00 |
| 2024 | $138.10M | $31.87M | $0.00 |
| 2023 | $101.21M | $-569.00K | $0.00 |
| 2022 | $53.16M | $-99.32M | $0.00 |
9 analysts cover CTMX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.